{
  "title": "PepMLM: Target Sequence-Conditioned Generation of Therapeutic Peptide Binders via Span Masked Language Modeling",
  "url": "https://openalex.org/W4387892965",
  "year": 2023,
  "authors": [
    {
      "id": "https://openalex.org/A2362543866",
      "name": "Chen Tian-lai",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Dumas, Madeleine",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Watson, Rio",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303470415",
      "name": "Vincoff, Sophia",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Peng, Christina",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A2103347462",
      "name": "Zhao Lin",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303470414",
      "name": "Hong, Lauren",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Pertsemlidis, Sarah",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Shaepers-Cheu, Mayumi",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A5016943256",
      "name": "Wang Tian-zi",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Srijay, Divya",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303470413",
      "name": "Monticello, Connor",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Vure, Pranay",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Pulugurta, Rishab",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Kholina, Kseniia",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Goel, Shrey",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303470426",
      "name": "DeLisa, Matthew P.",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Truant, Ray",
      "affiliations": []
    },
    {
      "id": null,
      "name": "Aguilar, Hector C.",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303470427",
      "name": "Chatterjee, Pranam",
      "affiliations": []
    }
  ],
  "references": [
    "https://openalex.org/W4383957026",
    "https://openalex.org/W2980127096",
    "https://openalex.org/W3011413773",
    "https://openalex.org/W2789187327",
    "https://openalex.org/W3108929519",
    "https://openalex.org/W2950954328",
    "https://openalex.org/W4318071656",
    "https://openalex.org/W4366823175",
    "https://openalex.org/W4317437864",
    "https://openalex.org/W2936686072",
    "https://openalex.org/W2591535357",
    "https://openalex.org/W4297235560",
    "https://openalex.org/W3152750978",
    "https://openalex.org/W4367049161",
    "https://openalex.org/W3165143074",
    "https://openalex.org/W4288066876",
    "https://openalex.org/W2989630699",
    "https://openalex.org/W3146944767",
    "https://openalex.org/W3013504322",
    "https://openalex.org/W4281557145",
    "https://openalex.org/W4387341290",
    "https://openalex.org/W3177828909",
    "https://openalex.org/W4327550249",
    "https://openalex.org/W2912930263",
    "https://openalex.org/W3186572052",
    "https://openalex.org/W3144701084",
    "https://openalex.org/W4205379795",
    "https://openalex.org/W3177500196",
    "https://openalex.org/W4321108300"
  ],
  "abstract": "Target proteins that lack accessible binding pockets and conformational stability have posed increasing challenges for drug development. Induced proximity strategies, such as PROTACs and molecular glues, have thus gained attention as pharmacological alternatives, but still require small molecule docking at binding pockets for targeted protein degradation. The computational design of protein-based binders presents unique opportunities to access \"undruggable\" targets, but have often relied on stable 3D structures or structure-influenced latent spaces for effective binder generation. In this work, we introduce PepMLM, a target sequence-conditioned generator of de novo linear peptide binders. By employing a novel span masking strategy that uniquely positions cognate peptide sequences at the C-terminus of target protein sequences, PepMLM fine-tunes the state-of-the-art ESM-2 pLM to fully reconstruct the binder region, achieving low perplexities matching or improving upon validated peptide-protein sequence pairs. After successful in silico benchmarking with AlphaFold-Multimer, outperforming RFDiffusion on structured targets, we experimentally verify PepMLM's efficacy via fusion of model-derived peptides to E3 ubiquitin ligase domains, demonstrating endogenous degradation of emergent viral phosphoproteins and Huntington's disease-driving proteins. In total, PepMLM enables the generative design of candidate binders to any target protein, without the requirement of target structure, empowering downstream therapeutic applications.",
  "full_text": "PepMLM:TargetSequence-ConditionedGenerationofTherapeuticPeptideBindersviaSpanMaskedLanguageModeling\nTianlaiChen,\n1\nMadeleineDumas,\n2,3\nRioWatson,\n1\nSophiaVincoff,\n1\nChristinaPeng,\n4\nLinZhao,\n1\nLaurenHong,\n1\nSarahPertsemlidis,\n1\nMayumiShaepers-Cheu,\n2\nTianZiWang,\n1\nDivyaSrijay,\n1\nConnorMonticello,\n4\nPranayVure,\n1\nRishabPulugurta,\n1\nKseniiaKholina,\n1\nShreyGoel,\n1\nMatthewP.DeLisa,\n5-7\nRayTruant,\n4\nHectorC.Aguilar,\n2\nPranamChatterjee\n1,8,9,†\n1. DepartmentofBiomedicalEngineering,DukeUniversity2. DepartmentofMicrobiologyandImmunology,CollegeofVeterinaryMedicine,CornellUniversity3. DepartmentofMicrobiology,CollegeofAgricultureandLifeSciences,CornellUniversity4. DepartmentofBiochemistryandBiomedicalSciences,McMasterUniversity5. MeinigSchoolofBiomedicalEngineering,CornellUniversity,Ithaca,NY,USA6. RobertF.SmithSchoolofChemicalandBiomolecularEngineering,CornellUniversity,Ithaca,NY,USA7. CornellInstituteofBiotechnology,CornellUniversity,Ithaca,NY,USA8. DepartmentofComputerScience,DukeUniversity9. DepartmentofBiostatisticsandBioinformatics,DukeUniversity\n†\nCorrespondingauthor:pranam.chatterjee@duke.edu\nAbstract\nTarget proteins that lack accessible bindingpocketsandconformational stabilityhaveposedincreasingchallengesfordrugdevelopment.Inducedproximitystrategies,suchasPROTACsandmolecularglues,havethusgainedattentionaspharmacological alternatives, but still requiresmall moleculedockingat bindingpocketsfortargetedproteindegradation.Thecomputationaldesignofprotein-basedbinderspresentsuniqueopportunities to access \"undruggable\" targets, but have often relied on stable 3D structures orstructure-influencedlatentspacesforeffectivebindergeneration.Inthiswork,weintroducePepMLM,atargetsequence-conditionedgenerator of de novo linear peptidebinders. Byemployinganovel spanmaskingstrategythat uniquelypositionscognatepeptidesequencesattheC-terminusoftargetproteinsequences,PepMLMfine-tunesthestate-of-the-art ESM-2pLMtofullyreconstruct thebinder region, achievinglowperplexitiesmatchingorimprovinguponvalidatedpeptide-proteinsequencepairs.Aftersuccessfulin silicobenchmarkingwithAlphaFold-Multimer, outperformingRFDiffusiononstructuredtargets,weexperimentallyverifyPepMLM'sefficacyviafusionofmodel-derivedpeptidestoE3ubiquitinligasedomains,demonstratingendogenousdegradationofemergentviralphosphoproteinsandHuntington'sdisease-drivingproteins.Intotal,PepMLMenablesthegenerativedesignofcandidatebinderstoanytargetprotein,withouttherequirementoftargetstructure,empoweringdownstreamtherapeuticapplications.\nIntroduction\nThedevelopmentoftherapeuticslargelyreliesontheabilitytodesignsmallmolecule-orprotein-basedbinderstopathogenictarget proteinsof interest.\n1 \nThesebinderscaneitherbeusedasinhibitorsorasfunctionalrecruitersofeffectorenzymes.\n2 \nForexample,proteolysistargetingchimeras(PROTACs)ormoleculargluesareheterobifunctional small moleculesthat bindandrecruit endogenousE3ubiquitinligasesfortargetedproteindegradation(TPD).\n3,4 \nStill,thesesmallmolecule-basedmethodsrelyontheexistenceofaccessiblecrypticorcanonicalbindingsites,whicharenotpresentonclassically“undruggable”intracellularproteins.\n5,6\nWiththeadvent of deeplearning-basedstructurepredictiontoolssuchasAlphaFold2andAlphaFold3,\n7,8\ncombinedwithgenerativemodeling,\n1 \nalgorithmssuchasRFDiffusionandMASIF-Seedenableresearcherstoconductde novo proteinbinderdesignfromtargetstructurealone.\n9,10 \nNonetheless,muchoftheundruggableproteome, including dysregulated proteins such as transcription factors and fusion oncoproteins, areconformationallydisordered,thusbiasingdesigntoasmallsubsetofdisease-relatedproteins.\n1,6\nOverthepast fewyears, deeplearninghasrevolutionizednatural languageprocessing(NLP),particularlythroughtheimplementationoftheattentionmechanism.\n11\nThisfoundationaladvancementhastranscendedtheboundariesof natural languageanalysis, findingapplicationsinthemodelingof otherlanguages,suchasproteins, whicharefundamentallysequencesof aminoacids.\n12 \nInrecent times, several proteinlanguagemodels(pLMs), trainedondistincttransformerarchitectures,suchasProtT5,ProGen2,ProtGPT2,andtheESMseries, haveaccuratelycapturedcritical physicochemical propertiesof proteins.\n13–16 \nNotably, ESM-2currently stands as the state-of-the-art model in the realm of protein sequence encoding, essentiallyfunctioningasanencoder-onlymodelthatdiscernsco-evolutionarypatternsamongproteinsequencesviaamasked language modeling (MLM) training task.\n17,18 \nThese models have been extended to powerfulapplications, includingantibodydesign, thecreationof novel proteins, andstructureprediction, offeringastreamlinedapproachtoembeddinguseful proteininformation.\n14,15,17,18 \nRecently, ourlabhasleveragedtheexpressivityof pLMstobothgenerateandprioritizeeffectivepeptidicbindermotifstotargetsof interest,enablingdesignof peptide-guidedproteindegraders\n19–21 \nthataremodeledaftertheubiquibodyarchitecturedevelopedbyPortnoff,etal.\n22 \nAssuch,uAbsnowrepresentaprogrammable,CRISPR-likeapproachforTPD.Our earlymodels, Cut&CLIPandSaLT&PepPr, relyontheexistenceof interactingpartnersequencesasscaffoldsforpeptidedesign.\n20,21 \nMost recently, ourPepPrCLIPmodel generatesde novo peptidesbyfirstsamplingtheESM-2latent spacefornaturalisticpeptidecandidates,andthenscreeningthesecandidatesthroughacontrastivemodel todeterminetarget sequencespecificity.\n23 \nHowever, apurelyde novo,targetsequence-conditionedbinderdesignalgorithmhasyettobedeveloped.\nToachievethisgoal,weintroducePepMLM,anovelPeptidebinderdesignalgorithmviaMaskedLanguageModeling,builtuponthefoundationsofESM-2.\n17 \nPepMLMinnovatesbyemployingaspanmaskingstrategythat uniquely positionstheentirepeptidebinder sequenceat theterminusof target proteinsequences,compelling ESM-2 toreconstruct theentirebindingregion(Figure1A). PepMLM-derivedlinear peptidesachievelowperplexities, matchingorimprovinguponvalidatedpeptide-proteinsequencepairsinthetestdataset, outperformthestate-of-the-art RFDiffusionmodel for peptidegenerationonstructuredtargetsinsilico,\n9 \nandexperimentallyexhibitdegradationofdifficult-to-drugdriversofHuntington’sdiseaseandemergentviral phosphoproteinswhenincorporatedintotheuAbarchitecture. Overall, byfocusingonthecompletereconstructionofpeptideregions,PepMLMrepresentsthefirstexampleoftarget-conditioneddenovobinderdesignfromsequencealone,thusfacilitatingadeeperunderstandingofbindingdynamicsandpavingthewayforthedevelopmentofmoreeffective,therapeuticbinderstoconformationallydiverseproteinsofinterest.\nResults\nPepMLM leverages span masking on ESM-2 embeddings for de novo generation of target-bindingpeptides\nWetrainedPepMLMusingexistingpeptide-proteinbindingdatasourcedfromtherecentPepNNtrainingsetandthegold-standardPropediadataset.\n24,25 \nWesubjectedourcurateddatasettoafiltrationprocessbasedonthelengthsofthebinderandtargetproteinsequences,whichwereconfinedto50and500respectively.Toremoveredundancies, weappliedahomologyfilterthresholdedat 80%, resultinginafinaltrainingsetof\n10,000samplesandleaving203samplesfortesting.\n26 \nEachentryinthedatasetcomprisedaconcatenatedproteinandbindersequence.Duringthetrainingphase,wemaskedtheentirepeptidesequence,taskingthemodeltoreconstructthemviatheESM-2-650Mmodel.Thediscrepancybetweenthegroundtruthbinderandthereconstructedbinderinducesacrossentropyloss,therebyforcingparameterupdatesviagradientdescent.Postfine-tuning,wegeneratepeptidebindersofspecificlengthsbyprovidingthemodelwithatargetproteinsequence and a user-defined number of mask tokens, as illustrated in Figure 1A. Final settings andhyperparametersusedtotrainourmodelarepresentedinSupplementaryTable1.\nWeconsideredtwodistinct decodingstrategiesduringthegenerationphase. Thedefault strategy,akintoESM-2orBERT-stylemodels,\n17 \nemploysgreedydecoding,whereinthetokenwiththehighestprobabilityisselectedat eachsite. Despiteitsefficacy, greedydecodingislimitedtothegenerationofasinglepeptidebinder.Toaugmentthediversityofthepeptides,weintroducedtop-ksampling,allowingPepMLMtorandomlyselectfromthetopk probabletokensateachsite.Inthisdecodingstrategy,weevaluatedperplexityalongsidevariousk values,rangingfrom2to10,onthetestsetoftargetproteins.Foreachtargetprotein,wegenerated10bindersofthesamelengthasthegroundtruthbinder.Weobservedthatask increased,perplexityalsorose,indicatingadecreaseinmodelconfidence(SupplementaryFigure1).Whilehigherkvaluesyieldedmorediversebindersequences,theyalsocorrespondedwithanincreaseinthenumberofoutliers.Tofindabalancebetweensequencediversityandmaintainingmodel confidence(asindicatedbythelowerperplexity), wesettledonk=3asourfinalselection.\nTosubstantiatetheefficacyofthegeneratedpeptides,weconductedacomprehensiveseriesofcomputationalbenchmarkswithtestsetpeptide-targetpairs.Thetotal203testsettargetproteinswereutilizedtogenerateone peptide binder each, employing pre-trained ESM-2 embeddings and PepMLM. Subsequently, thepseudo-perplexityof thebinderregionwascomputedforfourgroupsof target protein:binderpairs. Foramajorityofthetestset,knownbindersexhibitedareasonableperplexityrange,withonlyafewoutliers(thosewithaperplexity>40), validatingthePepMLM’seffectiveabilitytomodelthemaccurately(Figure1BandSupplementaryTable2).AcomparativeanalysisrevealedthatthebindersgeneratedbyPepMLMexhibitedlowerperplexityvalues, suggestingahigherlikelihoodof themmakingstablebindinginteractionswiththetarget(Figure1B).Moreover,ourdistributionanalysisrevealedthatPepMLMcloselymirrorsthedistributionpeakofrealbinders,adeviationfromthedistributionshiftsobservedwiththeoriginalESM-2modelaloneandwithrandomlygeneratedbinders(Figure1C).Weco-foldedtwotopgeneratedbinders,exhibitinghighipTMscores,withtheirrespectivetargetproteinsusingAlphaFold-MultimerthroughColabFold,\n27\nandoverlayedtheirpositionswiththat of PDB-validatedtest binderstothosetargets(Figure1D).Weobservehighalignmentbetween the generated and test peptides, highlightingthemodel'sproficiencyincapturingtheinherentconditionaldistributionsassociatedwithpeptide-proteinbinding.\nPepMLMperformsstronglyincomparisontoRFDiffusiononstructuredtargetsinsilicoandinvitro\nNext, tobenchmarkPepMLM’sgenerationquality, weco-foldedthetest andgeneratedbinderswiththeirrespective target proteins utilizing AlphaFold-Multimer, which has been proven effective at predictingpeptide-proteincomplexes.\n28,29 \nThepLDDTandipTMscores,verifiedmetricswithinAlphaFold2,\n7 \nfunctionascriticalindicatorsofthestructuralintegrityandthepotentialinterfacebindingaffinityofpeptide-proteincomplex,respectively, providingaquantitativeassessmentofourgeneration.TheextractedipTMandpLDDTvaluesfrom our benchmarking indicated a statistically significant negative correlation (p<0.01) with PepMLMperplexity, affirmingthemodel'sreliabilityat prioritizingbinderswithstablebindingcapacitytothetarget(SupplementaryFigure2).SubsequentanalysisinvolvedsortingthetestsetbasedontheiripTMvaluesandcontrastingthesewiththeipTMvaluesoftheassociatedPepMLM-generatedbinders.Ouranalysisyieldedahit rateexceeding38%(Figure2A).WhenapplyingthesameevaluationprocesstoRFDiffusionforbinderdesignonthetestset,thehitratewasbelow30%(Figure2B),suggestingPepMLM’scomparativeadvantageindesigningpeptidebinderstostructuredtargets, potentiallyreducingtheneedforextensivedownstreamexperimentalscreening.\nWhen evaluating generated peptide binderswithipTMscoressurpassingthoseof thetest binders, weclassifiedthemintothreedistinctgroupsbasedonipTMscorethresholds:ClassI(bothtestandgeneratedbinderswithipTM≥0.7),ClassII(generatedbinderswithipTM≥0.7,buttestbinderswithipTM<0.7),andClassIII(bothgeneratedandtestbinderswithipTM≤0.7).Foreachclass,threerepresentativecomplexes\nwerechosenforjointvisualizationwiththetestbinder(SupplementaryFigure3andSupplementaryTable3).ObservationsfromClassesIandIIindicatethatdespitethegeneratedbinderspossessingdistinctsequencecompositionscomparedtothetestbinders,theytendtotargetthesamebindingpocketandexhibitsimilarstructuralconformations.Thispatternsuggeststhatourlanguagemodel-baseddesignapproachsuccessfullycapturesstructuralinformationofpeptide-proteinbinding.Conversely,inClassIII,characterizedbyloweripTMvalues,wenoteddistinctbindingmodesbetweengeneratedandtestbinders.ThegeneratedbindersappearedtooccupymoreoptimalbindingpositionsaccordingtoAlphaFold-Multimerpredictions(SupplementaryFigure3).However,evenwiththehighpLDDTvaluesfromAlphaFold,itremainschallengingtodefinitivelyascertainwhetherourbindersexhibit uniquebindingmodesoriftheseobservationsareattributabletolimitationsinAlphaFold2-Multimer modeling. Therecent AlphaFold3model, onceopen-sourced, mayprovidestrongerpredictionsinfuturestructure-basedbenchmarkingefforts.\n8\nTo overcome these shortcomings, we sought toexperimentallytest PepMLMvs. RFDiffusion-generatedbinderstotheextracellulardomain(ECD)ofNCAM1/CD56,aproteininvolvedincell-to-celladhesion,whichplays critical roles in neural development and synaptic plasticity, and has been implicated in cancerprogression.\n30 \nUsingtheECDsequenceofNCAM1forPepMLMinputanditsstructureforRFDiffusioninput,wegeneratedandsynthesizedfourlinearpeptidesfromeachmethod(SupplementaryTable4)andperformedasandwichELISAatanNCAM1ECDconcentrationof1.37µM,usingthepeptideasthecapturebinder.Wefirst observedasignificant increaseinabsorbancebetweeneachpeptide’sinteractionwithNCAM1vs.thenegative PBS control. We further notedthat thetopPepMLMpeptide, NCAM1_pMLM_4, demonstratessignificantlystrongerbindingthanall fourRFDiffusionpeptidesat theequivalent concentrationof NCAM1(Figure2C).\nPepMLM-deriveduAbsdegradeHuntington’sdisease-relatedproteinsinvitro\nHavingdemonstratedPepMLM’scomparativelystrongbindergenerationtoRFDiffusioninbothinsilicoandinvitrocontexts, wenextevaluatedPepMLMpeptidesviafusiontoE3ubiquitinligasedomains,generatinguAbstodegradepathogenicproteinsinhumancells(Figure3A).\n31 \nWefocusedour attentiononHuntington’sdisease,amonogenicdominantneurologicaldisorderaffectingmorethan1in10000adults,causedprimarilybyanexpandedCAGrepeatinexon1oftheHTTgene,thusproducinganextendedpolyglutamine(polyQ)tractandresultinginaggregation-pronemutanthuntingtinprotein(mHTT).\n32 \nRecently,ithasbeenshownthatgenetic knockdown of the mismatchrepair-associatedMSH3proteinreducesandinhibitsmHTTrepeatexpansion.\n33,34\nHere,wethussoughttodegradeMSH3atthepost-translationallevel.\nFirst,todesignpeptidesforMSH3degradation,weemployedgreedydecodingtodeterminetheoptimalbinderlengththatyieldedthelowestperplexity,followedbythegenerationofbindersusingtopk sampling,wherekwasfixedat 3aspreviouslydescribed(SupplementaryTable4).AftercloningthesepeptidesintoouruAbbackboneandtransfectingintoHEK293Tcells,whichexpressMSH3athighlevels,weconductedWesternblottingonwhole-cellproteinextractswithMSH3-selectiveprimaryantibodies.Ourresultsdemonstratethatselect PepMLM-generated “guide” peptides, most notablyMSH3_pMLM_7, inducerobust degradationofMSH3whenfusedtoE3ubiquitinligasedomains,demonstratingreducedproteinlevelsrelativetothatofthenon-targetingcontrolpoly-glutamineuAb(Figure3BandSupplementaryTable4).WenextsoughttodegradethemHTTproteinitself.Todothis,weutilizedTruHDfibroblasts,agenomicallystablelinewhichexpressesthemHTTproteinat aclinically-relevant CAGrepeat lengthof Q43.\n35 \nAsthelineisheterozygouswithbothQ43/Q17alleles,wedesignedPepMLMpeptidestargetingexon1withapolyQrepeatof43,andscreenedthesepeptidesforthosewithhighperplexitiesfor,andthuspoorbindingpredictionto,theQ17variant.Afterdown-selecting5optimalcandidates(SupplementaryTable4),wetransfectedtheTruHDlineandmeasuredHTTdegradationwiththeEPR5526antibodyrecognizingthefirst100aminoacidsofHTTthatincludesthepolyQregion.Weshowthat3ofthe5PepMLM-designedpeptidesdemonstraterobustdegradationofHTT,with Q43_pMLM_3 demonstrating almost complete ablation (Figure 3C). Future work will establishthespecificityofthesepeptidestotheQ43variant.\nPepMLM-deriveduAbsdegradeemergentviral phosphoproteins\nFinally, we investigated whether PepMLM-derived uAbs could induce degradation of critical viral targetproteins.Asakeytargetclass,weselectedtheviralphosphoprotein(P)basedonitsrelativelyhighsequence\nhomologyamongststrainsoftheselectedviruses,aswellasitscriticalroleinviraltranscriptionandgenomereplication. Psequenceswereselectedfortwoemergingdeadlyviruseswithhighpandemicpotential,thehenipavirusesNipahvirus(NiV)andHendravirus(HeV), bothof whichposesignificant threatstohumanhealthwithrecordedmortalityratesof50-100%.\n36,37 \nAthirdPsequencewasselectedfortheendemicvirushumanmetapneumovirus(HMPV), whoseinfectionsoccur morefrequentlythanNiVandHeV, displayingseasonalcold-likesymptomsthataresevereandsometimesfatalinyoungchildrenandelderlypopulations.\n36\nTherearefewtonovaccinesorantiviraltreatmentsapprovedforhumanuseforthesethreeviruses.ForthesethreePproteins,60PepMLM-designeduAbsweredesigned(SupplementaryTable4)andscreenedfortheirabilitytoinduceproteasomal degradationof their respectiveviral Ptarget throughWesternblot analysis(Figure 4). Of the 60 uAbs screened, we observed a total of 16 demonstrating 25-49%reduction inphosphoproteinleveland8withover50%Pproteinreduction,suggestinganoverallhit-rateofaround40%,instrong agreement with our in silico hit rate shown in Figure 2A (Figure 4A-C). Specifically, sevenHMPV-targetinguAbsexhibitedover50%reductionofHMPVPproteinexpressionanduAbsNiV_2,3,8,11,12, and17demonstratedmoderatetostrongdegradationoftheNipahvirusPprotein.HeV_2showedthemost drasticchangeinhenipaviral Pproteinpresencewitha~56%reduceddetectionofHeVP.Together,theseresultsprovidestrongevidenceofPepMLM’sabilitytoacceleratedevelopmentoftherapeuticstocurrentandemergentdiseases.\nDiscussion\nBysimplyredesigningaguideRNA,theCRISPR-CassystemenablestargetingandmodificationofalmostanyDNA sequence, a programmable method that has revolutionized biology.\n38 \nSpecifically, with therecentengineeringofprotospaceradjacentmotif(PAM)-relaxedCasvariants,thereisminimalrestrictionastowhichuser-definedDNAsequencescanbeboundandedited.\n39,40 \nToenablesimilarprogrammabletargetingofanyprotein,here,weintroducePepMLM,thefirstdenovobinderdesignalgorithmdirectlyconditionedonlyonthetargetsequenceofaprotein,withoutanystructuralrequirement.ByusinggeneratedpeptidesasguidesforE3ubiquitinligasedomains,andeventuallyotherpost-translationalmodificationdomains,thisworkservesasastepforwardtowardsdevelopingafullymodularproteomeeditingsystem.\nTothispoint,wehadutilizedthelightweightESM-2-650Mmodel,enablingflexiblefine-tuningandinference.Toassesstheperformanceof largermodels, wenotethat weadditionallyfine-tunedESM-2-3B\n17 \nforpeptidegeneration(PepMLM-3B)andevaluatedit usingthesamemethodologyasemployedfortheESM-2-650MversionofPepMLM(PepMLM-650M).However,asillustratedinSupplementaryFigure4,wedidnotobserveasubstantialimprovementineitherperplexityorhitrateforPepMLM-3B(36.02%).Consideringtheassociatedresourceandinferencecosts,weprovideourPepMLM-650Mmodelasanaccessibleresourceforeffectivelinearpeptidegeneration.\nNonetheless,weenvisionthatfurtherimprovementscanbemadetoPepMLM-650M,enablingitsadoptionasauniversaltoolforpeptidebinderdesign.Forexample,PepMLMcanberetrainedwithmodification-awareandvariant-aware pLMembeddings toenablespecificitytopost-translational isoformsover wild-typeproteinstates.\n41 \nOur future experimental work directions will include biochemical and molecular validation andcharacterizationoftheantiviraltherapeuticpotentialoftopselecteduAbswithintheMEandCEgroupstestedfortheemergent viraltargets.WealsoplantointegratePepMLMgenerationwithhigh-throughputlentiviralscreeningtofurtherevaluateitshitrateandinputexperimentaldatabackintothealgorithm,creatinganactivelearning-based optimization loop. As a note, we have not applied any experimental optimization ofPepMLM-derivedpeptidebinders,includingfurtherstabilizationviacyclizationorstapling,modificationswhichmayimprovetherapeuticutility.\n42,43 \nIntotal,weenvisionthatthroughadditionaldevelopment,ouraccessiblepeptidegenerator,coupledwithvariantsofouruAbarchitecture,willenableaCRISPR-analogoussystemtobindandmodulateanytargetprotein,whetherstructuredornot.\nMethods\nDataCuration\nInthedatacurationphase,proteinandpeptidecomplexeswereamalgamatedfromthePepNNandPropediadatabases.\n24,25 \nInitially, redundancybetweenthetwodatasetswaseliminated, followedbytheutilizationofMMseqs2toclustertheremainingproteinsequences,settingathresholdof0.8.\n26 \nWhenproteinsequenceswereidentifiedwithinthesameclusterandexhibitedidentical bindersequences, asinglesequencewasretained.Thiswasfollowedbyamanualfilteringprocess,whereinproteinsequencesweresortedandthoseexhibitinghighsimilarity(thresholdof80%)wereremovedtofurthermitigatehomologyissues.Consequently,adatasetcomprising10,203entrieswasamassed,fromwhich10,000wererandomlyallocatedfortrainingand203fortesting.Themaximumlengthsforthebinderandproteinsequenceswereestablishedat50and500,respectively.\nConditional PeptideModeling\nPeptidebindersaremodeledinadistinctivemanner,whereinthepeptidesaremodeledconditionallybasedonthefullproteinsequence.Let representthetargetproteinsequenceoflength anddenotethebinderoflength .Theproteinandpeptidesequencesareconcatenated,incorporatingspecial tokensof start, end, andpadding. Masklanguagemodelingtransformsthisintoaconditionalmodelingproblem,wheretheobjectiveistoreconstruct given andentiremasked region.Innaturallanguageprocessing,suchatechniqueisclosetospanmaskingwhichhasdemonstratedenhancedperformanceinlanguagemodeling.\n44,45\nTheentiremodelisupdatedwithMaskedLanguageModel(MLM)loss,whichcanberepresentedas:\nThroughthismethodology,thediscrepancybetweenthegeneratedbindersandthegroundtruthisminimized,facilitatingtheapproximationoftheconditionalprobability, .\nPepMLMTraining\nThepre-trainedproteinlanguagemodel,ESM-2,wasutilizedtofacilitatefullparameterfine-tuning.ESM-2,atransformer-based model, is adept at discerningcoevolutionarypatternsacrossproteinsequences. Theconcatenatedproteinandpeptidesequencesweretokenizedattheaminoacidlevelandinputintothemodel.Deviatingfromtheoriginal trainingstrategyof ESM, theentirebindersequencewasexclusivelymasked,compellingthemodeltolearntherelationshipbetweenthepeptidebinderandtheprotein.TheESM-2-650MandESM-2-3BmodelswerebothtrainedforPepMLM.BothversionsweretrainedonanNVIDIA8xA100640GBDGXGPUsystemwithPytorch2.01andPython3.10.10.SpecificparametersareshowninSupplementaryTable1.\nPepMLMGeneration\nDuringthegenerationphase,thetargetproteinsequence,alongwithadesignatednumberofmasktokens(atend),wasinputintothemodel.Subsequently,themodelgreedilydecodeslogitsateachmaskedpositiontoidentify peptide binders. To infuse greater diversity into the generation process, top k sampling wasimplemented,whereinthemodelrandomlyselectsthetopkhighestprobabilitylogitsateachmaskedposition.\nPseudo-PerplexityofPepMLM\nThe pseudo-perplexity of ESM-2 was adapted to focusspecificallyontheevaluationof peptidebindergeneration.Notably,theperplexitycalculationisconfinedtothebinderregion,or,inotherwords,themaskedregions.Mathematically,thepseudo-perplexityisdefinedas:\n\nIn this equation, representsthebinder sequenceand isthelengthof thebinder sequence. Thismodificationensuresamorefocusedevaluationofthegeneratedpeptidebinders,aligningwiththeconditionalmodelingapproachadoptedinthisstudy.\nGeneratedPeptideBenchmarking\nToassesstheefficacyofthegeneratedpeptidebinders,twobenchmarkingstudieswereconducted:oneonthetestsetandanotheronselectedcriticalproteins.Inthetestsetbenchmarking,top-ksampling(k=3)wasemployedtogenerateasinglepeptidebinderforeachtargetprotein.Additionally,theoriginalESM-2modelwas utilized to generate peptides, andrandompeptidesof equivalent lengthwerecreated. For ESM-2generation,specifically,masktokensofthesamelengthwereaddedattheendoftargetproteinsequencesforanalogousmodel predictionanddecodingasforPepMLM. Theperplexityof thePepMLMwascomparedacrossfourgroups.PepMLM-generatedbindersandtestbinderswerefoldedusingtheAlphaFold2ColabFoldversion1.5.2, inconjunctionwiththeproteinsequences. FoldingmetricsincludingpLDDTandipTMweregathered,whichwereutilizedtocorrelateperplexityfindings.Foreachtesttargetprotein,theipTMscoresofthetest andgeneratedbinderswerecomparedtodeterminetheoverallhitrate.Notice,astop-k samplinggenerateswithrandomness,thehitratemightvaryorincreasewithdifferentrunsorkoptions.Fortheproteinsidentifiedascritical,themodelproducedeightbinders,eachofalengthof15residues,usingtop-ksampling(k= 3). These binders were synthesized for specific target proteins tofacilitatesubsequent experimentalevaluations.\nCo-FoldingComplexVisualization\nFor the visualization of AlphaFold-Multimer co-folding results from PepMLM-generated binder-proteincomplexes,aninitialalignmentwiththecorrespondingtestcomplexwasperformedusingBiopythonversion1.8.3,facilitatedacomparativevisualizationofselectedcomplexes,encompassingboththegeneratedandtestbinders. Inthesevisualizations, thetarget proteinwasdepictedinyellow, contrastingwiththetest andgeneratedbinders, coloredinblueandred, respectively. Thevisualizationswereexecutedusingpy3Dmolversion2.0.4.\nRFDiffusionGeneration\nInparalleltothePepMLMapproach,RFDiffusionwasemployedtodesignpeptidebindersforbothcases.Forthegiventestset,RFDiffusionwastaskedwithgeneratingonepeptidebinderpertargetprotein,matchingthelengthspecifiedbythegroundtruthbinders.ThepredictedstructureswerethenconvertedintosequencesusingProteinMPNNwithinitialguessandnumberofcyclesof3.Fortheselectedcriticalproteins,RFDiffusionandProteinMPNNgenerated8candidatebinders, eachcomprising15residues,underidenticalparametersettings as testset generation. RFDiffusion inference code on ColabFold can be found here:https://colab.research.google.com/github/sokrypton/ColabDesign/blob/v1.1.1/rf/examples/diffusion.ipynb\nSandwichELISA\nLinearpeptidestoNCAM1(SupplementaryTable4)werepurchasedat>80%purityfromCPCScientific.Inbrief, 96-well plates(Corning, 9018)werecoatedwith2 μ g/mLofpeptides(BiomatikRPU40704)dilutedin1xPBS,pH7.4,atavolumeof50 µLperwellin4 °Covernight.Followingthis,theplateswerewashedwith1xPBST(PBS,0.1%(v/v)Tween20)threetimesandadded200 µLofblockingbuffer(3%bovineserumalbumin(BSA)in1xTBST)perwellovernightat4 °C.PBSorrecombinantNCAM1(ManufacturerProductNo.)weredilutedintriplicateat1.37μ Min1xPBSandaddedtotheELISAplatesfor1hat37\no\nC.Theplateswerewashedthreetimeswith1xPBS-T,thensamplesweretreatedwithbiotinylatedAnti-CD56(NCAM)monoclonalantibody(ThermoFisher, Cat #13-0567-82;diluted1:5000).Theplateswerethenwashedthreetimeswith1xPBS-Tandincubatedfor1 hatroomtemperaturewithHRP-conjugatedstreptavidin(ThermoFisher,Cat#N100;diluted1:20,000),withshakingat450 rpm.Followinganadditionalthreewasheswith1xPBS-T,100 µLof 3,3’-5,5’-tetramethylbenzidinesubstrate(1-StepUltraTMB-ELISA; ThermoFisher, 34029)wasaddedtoeachwell,andtheplateswereincubatedatroomtemperatureindarkness.Thereactionwasquenchedbyadding100 µLof2 MH2\nSO4,andabsorbancewasquantifiedatawavelengthof450 nmutilizingaFilterMaxF5microplatespectrophotometer(Agilent).\n\nGenerationofplasmids\nAll uAbplasmidsweregeneratedfromthestandardpcDNA3vector, harboringacytomegalovirus(CMV)promoter and a C-terminal P2A-GFP cassette as a transfection control. An Esp3I restriction site wasintroducedimmediatelyupstreamoftheCHIP Δ TPRCDSandflexibleGSGSGlinkerviatheKLDEnzymeMix(NEB)followingPCRamplificationwithmutagenicprimers(Genewiz).ForuAbassembly,PepMLM-derivedpeptidesequences(SupplementaryTable4)werehumancodon-optimizedforcomplementaryoligogeneration(Genewiz). OligoswereannealedandligatedviaT4DNALigaseintotheEsp3I-digesteduAbbackbone.Assembledconstructsweretransformedinto50µLNEBTurboCompetentEscherichiacoli cells,andplatedontoLBagarsupplementedwiththeappropriateantibioticforsubsequentsequenceverificationofcoloniesandplasmidpurification(Genewiz).\nSequencesforhumancodon-optimizedphosphoproteingenesforNiV(GenBankAY029767),HeV(GenBankMN062017),andHMPV(GenBankAAS22075)weredesignedwithHAtagsontheirN-terminiandflankedwithrestrictionenzymerecognitionsitesforKpnIandXhoIontheir3’and5’ends,respectively,forligationintoamammalianpCAGGSvector.\nCell culture\nHEK293TcellsweremaintainedinDulbecco’sModifiedEagle’sMedium(DMEM)supplementedwith100units/mlpenicillin,100mg/mlstreptomycin,and10%fetalbovineserum(FBS).ThePepMLMpeptides(500ng)plasmidsweretransfectedintocells(4x10\n5\n/wellina12-wellplate)withLipofectamine2000(Invitrogen)inOpti-MEM(Gibco).TruHD-Q43Q17McellsweremaintainedinMinimumEssentialMediumEaglewithEarle’sSalts(EMEM)supplementedwith15%FBS, 1%NEAA(Gibco),and1%GlutaMAX(Gibco).ThePepMLMpeptidesweretransfectedintothefibroblastsusingtheSGcellline4D-NucleofectorXkit(Lonza).Forviralproteindegradation,transfectionsweredonewithHEK293Tcellsatapproximately90%confluencyin6-wellplatesusinga4:1µL/µgratioof polyethylenimine(PEI) MaxtoDNA, followingthetransfectionreagentmanufacturer’sprotocol.TargetPplasmidsweretransfectedata1:1ratiowithuAbplasmidsforatotalof2µgof DNAper well inOptiMem. TransfectionsweresupplementedwithOptiMemat approximately5hposttransfection.\nMSH3Westernblotting\nOnthedayofharvest,cellswerewashedwith1XPBSanddetachedbyadditionof0.05%trypsin-EDTA,thenpelletedbycentrifugationat1000rcffor5min.Cellswerethenlysedandsubcellularfractionswereisolatedfromlysatesusinga1:100dilutionof proteaseinhibitor cocktail (MilliporeSigma) inPierceRIPAbuffer(ThermoFisher).Specifically,theproteaseinhibitorcocktail-RIPAbuffersolutionwasaddedtothecellpellet,themixturewasplacedonicefor30minfollowedbycentrifugationat15,000rpmfor15minat4\no\nC.Thesupernatantwascollectedimmediatelytoapre-chilledPCRtube,andtheproteinconcentrationwasquantifiedusing a Pierce BCA Protein Assay kit (Thermofisher). After adding 4X Bolt™ LDS Sample Buffer(ThermoFisher)with5%β- mercaptoethanolina3:1ratioto20µgofprotein,themixturewasincubatedat95o\nCfor10minpriortoimmunoblotting.Immunoblottingwasperformedaccordingtostandardprotocols.Briefly,samples were loaded at equal volumesintoBolt™Bis-TrisPlusMini ProteinGels(ThermoFisher) andseparatedbyelectrophoresis.iBlot™2TransferStacks(Invitrogen)wereusedformembraneblottransfer,andafterblockingat 1hroom-temperaturein1%NonfatDryMilk(Thermofisher)in1XTBS-T(Thermofisher),proteinswereprobedwithmouseanti-MSH3antibody(SantaCruzBiotechnology,Cat#sc-271080;diluted1:2000)andmouseanti-GAPDHantibody(SantaCruzBiotechnology, Cat #sc-47724; diluted1:10000)forovernight incubationat 4\no\nC. Theblotswerewashedthreetimeswith1XTBSTfor10mineachandthenprobedwithasecondaryantibody,goatanti-mouseIgG(H+L)Poly-HRP(ThermoFisher,Cat#32230,diluted1:5000)for1hat roomtemperature. Followingthreewasheswith1XTBSTfor10mineach,blotsweredetectedbychemiluminescenceusingChemiDoc™TouchImagingSystem(BioRad).\nHTTWesternblotting\nForTruHD-Q43Q17Mcells,onthedayofharvest,cellswerewashedwith1xPBS,thenlysedandscrapedoffusingradioimmunoprecipitationassaybuffer(RIPA;50 mMTris-HClpH8.0,150 mMNaCl,1%NP-40,0.25%\nsodiumdeoxycholate, 1 mMEDTA)withproteaseandphosphataseinhibitors(Thermo)onice.Themixturewasincubatedonicefor 5minutesfollowedbycentrifugationat 13,000rpmfor5minutesat 4\no\nC. ThesupernatantwascollectedandquantifiedusingtheBCAProteinAssayKit(Sigma).4xloadingbuffer(250mMTrispH6.8,40%glycerol,8%SDS,0.02%bromophenolblue)wasaddedtothesupernatantandincubatedat95\no\nCfor5minutes. Immunoblottingwasperformedusingprecast4-20%gradientgels(Bio-Rad)andthentransferredontoanImmobilon®-PPVDFmembrane(Millipore).Themembraneswereblockedin5%skimmilkpowderin1xTBS-T(50 mMTris-HCl,pH7.5,150 mMNaCl,0.1%Tween-20)at4\no\nCovernight,thenprobedwith rabbit anti-huntingtin antibody (Abcam, EPR5526, 1:5000) or rabbit anti-vinculin antibody (Abcam,EPR8185,1:5000)inthesamebufferforonehouratroomtemperature.Themembraneswerewashedthreetimeswith1xTBS-T, thenthreetimeswith2.5%skimmilkpowderin1xTBS-Tfor5minuteseach.Themembranesarethenprobedwithhorseradishperoxidase-conjugatedsecondaryantibodies(Abcam,1:50000)for 30minutesat roomtemperaturebeforebeingwashedagainandincubatedwithImmobilonWesternChemiluminescentHRPSubstrate(Millipore)andimagedwithMicroChemichemiluminescencedetector(DNRBio-imagingSystems).\nViral phosphoproteinWesternblotting\nHEK293Tcellswereharvested48hourspost-transfectionandlysedusing1Xradioimmunoprecipitation(RIPA,Millipore)buffercontainingcompleteproteaseinhibitor(Sigma).Thecellswereincubatedat4˚C,rocking,for40minbeforebeingvortexedat5minintervalsfor20min.Celllysatesupernatantswerecollectedfollowingcentrifugationat21,000xgfor30minat4˚C.Todenaturesamplesforsodiumdodecylsulfate-polyacrylamidegel electrophoresis (SDS-PAGE), cell lysatesweremixedandincubatedwith1.8%SDScontaining5%beta-mercaptoethanolfor10minutesat95˚Cbeforeloadingontoa10%acrylamide-TrisHClgels.Proteinswereseparatedat100Vfor2handthentransferredonto0.2µmpolyvinylidenedifluoride(PVDF)membranesat0.5Afor2h.Membraneswereblockedinphosphatebufferedsalinewith0.2%Tween20(PBST)containing4%bovineserumalbumin(BSA)beforestainingin1:1,000dilutionsof mouseanti-FLAG(Millipore, CAT:F1804), mouseanti- β- actin(SantaCruzBiotechnology, CAT: 47778), andrabbit anti-HA(Biolegend, CAT:923502) primaryantibodies. Secondaryantibodystainingwasperformedusing1:1,000dilutionsof goatanti-mouseAlexaFluor 647andgoat anti-rabbit AlexaFluor 488secondaryantibodies(Invitrogen, CAT:A21236andA11008, respectively). Blocking, primaryandsecondaryantibodymembraneincubationswereperformedrockingatroomtemperaturefor30min,1h,and30min,respectively.MembraneswererinsedwithPBST3timesfor5mineachfollowingantibodystaining.AllmembraneswereimagedusingaBio-Radimagerin respective Alexa Fluor channels. Densitometric quantification was performed using ImageLab forphosphoproteinandβ- actinbands.Backgrounddensitiesfromsamplesmock-transfectedwithpCAGGSvectoronlyweresubtracted. Then, sampledensitieswerenormalizedtotheir respectiveβ- actinsignalsbeforenormalizationtotheirrespectivephosphoprotein-onlycontrols. BargraphswereproducedusingGraphPadPrism,version10andtheschematicdiagramwasmadeusingBioRender.\nStatistical analysisandreproducibility\nAlldatawerereportedasaveragevalueswitherrorbarsrepresentingstandarddeviation(SD).Forsamplesperformedinindependent biological triplicates(n=3) or above, statistical significancewasdeterminedbyunpairedt test(*p<0.05,**p<0.01;***p<0.001;****p<0.0001).AllgraphsweregeneratedusingPrism10forMacOSversion14.4.1.Nodatawereexcludedfromtheanalyses.Theexperimentswerenotrandomized.Theinvestigatorswerenotblindedtoallocationduringexperimentsandoutcomeassessment.\nAuthorContributions\nT.C.designedthePepMLMarchitecture,curatedpeptide-proteindata,trainedandevaluatedtrainedmodels.T.C.,R.P.,andP.V. performedinsilicobenchmarking.L.H.andS.P.conductedsandwichELISAassaysandanalyzed results. R.W. performed MSH3 degradation assays, assisted by L.H., D.S., and T.Z.W. L.Z.constructedmHTTuAbsandC.P.performeddegradationassays,respectively.M.D.andM.S.C.performedviral phosphoprotein degradation assays. C.M. produced P protein-targeting uAbs. S.V. computationallydesigned PepMLMpeptidesfor experimental testing, assistedbyK.K. andS.G. M.P.D. superviseduAbconstructionforPproteindegradation.R.T.supervisedmHTTdegradationassays.H.C.A.supervisedPprotein\ndegradation assays. P.C., T.C., H.C.A. andM.D. wrotethemanuscript withinput fromall authors. P.C.conceived,designed,supervised,anddirectedthestudy.\nDataandMaterialsAvailability\nAll dataneededtoevaluatetheconclusionsinthepaperarepresent inthepaperandcoderepository:https://github.com/programmablebio/pepmlm.PepMLM-650MisalsohostedonHuggingFaceforacademicuseonly,withaneasy-to-usedemoforpeptidegeneration:https://huggingface.co/ChatterjeeLab/PepMLM-650M.All rawandprocesseddata(includingrawimmunoblots)havebeendepositedtotheZenodorepository:https://doi.org/10.5281/zenodo.11201091.\nCompetingInterests\nP.C.andM.P.D.isaco-founderofUbiquiTx,Inc.,andareinventorsofpatentsrelatedtogenetically-encodedproteomeeditingtechnologies.Theremainingauthorsdeclarenocompetinginterests.\nAcknowledgements\nWethanktheDukeComputeClusterandMarkIIISystemsforprovidingdatabaseandcomputeresourcesthathavecontributedtotheresearchreportedwithinthismanuscript.WealsothankSuhaasBhatandManvithaPonnapatiforcuratinginitialpeptidedatasets,andVenkataSrikarKavirayuniandAshleyHsuforassistinginPepMLMbenchmarking.\nDeclarations\nTheresearchwassupportedbyinstitutionalstartupfundstothelabofP.C.fromDukeUniversity,aswellasfundsfromtheWallaceH.CoulterFoundation,theCHDIFoundation,TheHartwellFoundationandNIHgrants3U54CA231630-01A1S4and1R21CA278468-01tothelabofP.C.TheworkwasalsofundedbyinstitutionalCornellfundsandNIHgrantR01AI109022tothelabofH.A.C.andbytheKrembilFoundationtothelabofR.T.\nReferences\n1. Chen,T.,Hong,L.,Yudistyra,V.,Vincoff,S.&Chatterjee,P.Generativedesignoftherapeuticsthatbindandmodulateproteinstates.Curr. Opin. Biomed. Eng. 28,100496(2023).2. Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and futureperspectives.Signal TransductionandTargetedTherapy6,1–48(2021).3. Békés,M.,Langley,D.R.&Crews,C.M.PROTACtargetedproteindegraders:thepastisprologue.Nat.Rev. DrugDiscov. 21,181–200(2022).4. Dong, G., Ding, Y., He, S. & Sheng, C. Molecular Glues for TargetedProteinDegradation: FromSerendipitytoRationalDiscovery.J. Med. Chem. 64,10606–10620(2021).5. Gao,H.,Sun,X.&Rao,Y.PROTACTechnology:OpportunitiesandChallenges.ACSMed. Chem. Lett.11,237–240(2020).6. Behan,F.M.et al. PrioritizationofcancertherapeutictargetsusingCRISPR-Cas9screens.Nature568,511–516(2019).7. Jumper,J.et al. HighlyaccurateproteinstructurepredictionwithAlphaFold.Nature596,583–589(2021).8. Abramson,J.et al. AccuratestructurepredictionofbiomolecularinteractionswithAlphaFold3.Nature1–3(2024).9. Watson, J. L. et al. Denovodesignof proteinstructureandfunctionwithRFdiffusion. Nature 620,1089–1100(2023).10. Gainza, P. et al. Denovodesignof proteininteractionswithlearnedsurfacefingerprints.Nature 617,176–184(2023).11. Vaswani,A.et al. Attentionisallyouneed.(2017)doi:10.48550/ARXIV.1706.03762.12. Ofer,D.,Brandes,N.&Linial,M.Thelanguageofproteins:NLP,machinelearning&proteinsequences.Comput. Struct. Biotechnol. J. 19,1750–1758(2021).\n13. Elnaggar, A. et al. ProtTrans: TowardUnderstandingtheLanguageof LifeThroughSelf-SupervisedLearning.IEEETrans. PatternAnal. Mach. Intell. 44,7112–7127(2022).14. Madani,A.et al. Largelanguagemodelsgeneratefunctionalproteinsequencesacrossdiversefamilies.Nat. Biotechnol. 41,1099–1106(2023).15. Ferruz,N.,Schmidt,S.&Höcker,B.ProtGPT2isadeepunsupervisedlanguagemodelforproteindesign.Nat. Commun. 13,1–10(2022).16. Rives,A.et al. Biologicalstructureandfunctionemergefromscalingunsupervisedlearningto250millionproteinsequences.Proc. Natl. Acad. Sci. U. S. A. 118,(2021).17. Lin,Z.et al. Evolutionary-scalepredictionofatomic-levelproteinstructurewithalanguagemodel.Science379,1123–1130(2023).18. Hie, B. L. et al. Efficient evolutionof humanantibodiesfromgeneral proteinlanguagemodels. Nat.Biotechnol. 1–9(2023).19. Chatterjee, P. et al. Targetedintracellular degradationof SARS-CoV-2viacomputationallyoptimizedpeptidefusions.CommunicationsBiology3,1–8(2020).20. Palepu, K. et al. Designof Peptide-BasedProteinDegradersviaContrastiveDeepLearning. bioRxiv(2022)doi:10.1101/2022.05.23.493169.21. Brixi,G.et al. SaLT&PepPrisaninterface-predictinglanguagemodelfordesigningpeptide-guidedproteindegraders.CommunicationsBiology6,1–10(2023).22. Portnoff,A.D.,Stephens,E.A.,Varner,J.D.&DeLisa,M.P.Ubiquibodies,syntheticE3ubiquitinligasesendowedwithunnaturalsubstratespecificityfortargetedproteinsilencing.J. Biol. Chem. 289,7844–7855(2014).23. Bhat, S. et al. DeNovoGenerationandPrioritizationofTarget-BindingPeptideMotifsfromSequenceAlone.bioRxiv2023.06.26.546591(2023)doi:10.1101/2023.06.26.546591.24. Abdin,O.,Nim,S.,Wen,H.&Kim,P.M.PepNN:adeepattentionmodelfortheidentificationofpeptidebindingsites.CommunicationsBiology5,1–10(2022).25. Martins, P. et al. Propediav2.3: Anovel representationapproachfor thepeptide-proteininteractiondatabaseusinggraph-basedstructuralsignatures.Front Bioinform3,1103103(2023).26. Steinegger,M.&Söding,J.MMseqs2enablessensitiveproteinsequencesearchingfortheanalysisofmassivedatasets.Nat. Biotechnol. 35,1026–1028(2017).27. Mirdita,M.et al. ColabFold:makingproteinfoldingaccessibletoall.Nat. Methods19,679–682(2022).28. Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv (2021)doi:10.1101/2021.10.04.463034.29. Johansson-Åkhe,I.&Wallner,B.Improvingpeptide-proteindockingwithAlphaFold-Multimerusingforcedsampling.Front Bioinform2,959160(2022).30. Sasca, D.et al. NCAM1(CD56)promotesleukemogenesisandconfersdrugresistanceinAML.Blood133,2305–2319(2019).31. Zöllner,S.K.et al. EwingSarcoma-Diagnosis,Treatment,ClinicalChallengesandFuturePerspectives.J.Clin. Med. Res. 10,(2021).32. Finkbeiner,S.Huntington’sDisease.ColdSpringHarb. Perspect. Biol. 3,(2011).33. Driscoll, R. et al. Dose-dependentreductionofsomaticexpansionsbutnotHttaggregatesbydi-valentsiRNA-mediatedsilencingofMSH3inHdhQ111mice.Sci. Rep. 14,1–11(2024).34. O’Reilly,D.et al. Di-valentsiRNA-mediatedsilencingofMSH3blockssomaticrepeatexpansioninmousemodelsofHuntington’sdisease.Mol. Ther. 31,1661–1674(2023).35. Hung, C. L.-K. et al. Apatient-derivedcellularmodel forHuntington’sdiseaserevealsphenotypesatclinicallyrelevantCAGlengths.Mol. Biol. Cell 29,2809–2820(2018).36. Gálvez, N. M. S. et al. Host ComponentsThat ModulatetheDiseaseCausedbyhMPV. Viruses 13,(2021).37. Gazal,S.et al. NipahandHendraViruses:DeadlyZoonoticParamyxoviruseswiththePotentialtoCausetheNextPandemic.Pathogens11,(2022).38. Wang, J. Y. &Doudna, J. A. CRISPRtechnology: Adecadeofgenomeeditingisonlythebeginning.Science379,eadd8643(2023).39. Walton,R.T.,Christie,K.A.,Whittaker,M.N.&Kleinstiver,B.P.Unconstrainedgenometargetingwithnear-PAMlessengineeredCRISPR-Cas9variants.Science368,290–296(2020).40. Zhao, L.et al. PAM-flexiblegenomeeditingwithanengineeredchimericCas9.Nat. Commun. 14,1–8(2023).\n41. Peng, Z., Schussheim, B. &Chatterjee, P. PTM-Mamba: APTM-AwareProteinLanguageModelwithBidirectionalGatedMambaBlocks.bioRxiv2024.02.28.581983(2024)doi:10.1101/2024.02.28.581983.42. Vinogradov, A. A., Yin,Y.&Suga,H.MacrocyclicPeptidesasDrugCandidates:RecentProgressandRemainingChallenges.J. Am. Chem. Soc. 141,4167–4181(2019).43. Moiola, M., Memeo, M. G. &Quadrelli, P. StapledPeptides-AUseful Improvement forPeptide-BasedDrugs.Molecules24,(2019).44. Joshi, M. et al. SpanBERT: Improving pre-training by representing and predicting spans. (2019)doi:10.48550/ARXIV.1907.10529.45. Raffel, C. et al. Exploringthelimitsof transferlearningwithaunifiedtext-to-text transformer. (2019)doi:10.48550/ARXIV.1910.10683.\nFigure 1. Overview and evaluation of the PepMLM model. (A)ThearchitectureofthePepMLMmodel.Basedonthefine-tuningofESM-2,themodelincorporatesthetargetproteinsequencealongwithamaskedbinderregionduringthetrainingphase. Duringthegenerationphase,themodelcanaccepttargetproteinsequencesandmasktokenstofacilitatethecreationofpeptidesofspecifiedlengths.(B)Perplexitydistributioncomparison.Theperplexityvalueswerecalculatedfortestandgeneratedpeptides,encompassingthetargetproteinsinthetestset.(C)Thedensitydistributionvisualizationofthelogperplexityvaluesfortarget-peptidepairs,encompassingtestpeptides,PepMLM-650M-generatedpeptides,ESM-2-650M-generatedpeptides,andrandompeptides.(D)AlphaFold-Multimerco-foldingexamplesofspecifiedtargetproteinsfromthePDBandsampledpeptidebindersgeneratedviaPepMLM-650M,withthepLDDTvaluesservingasthedeterminantforcolorcoding.ipTMscoresindicatestabilityofthebindinginterface,aproxyforbindingaffinity.\n\nFigure 2. Extrinsic evaluation of PepMLM-generated peptides insilicoandinvitro. (A)Insilicohit-rateassessmentofPepMLM.UtilizingAlphaFold-Multimer,ipTMscoreswerecomputedforboththegeneratedandtestpeptidesinconjunctionwiththetargetproteinsequence.TheentriesareorganizedinaccordancewiththeipTMscoresattributedtothetest set peptides. Thehit rateischaracterizedbythegeneratedpeptidesexhibitingipTMscores≥thoseof thetest peptides. (B)In silico hit-rateassessment of RFDiffusion. TheanalogousassessmentwasappliedforbindersgeneratedbyRFDiffusionasforPepMLM-derivedbindersinPartA.(C)ELISAbindingdataoftestedpeptidesat1.37uMofeitherNCAM1ECDorPBS.Absorbancewascalculatedat450nm.\n\nFigure3. Degradationof Huntington’sdisease-drivingproteinsinvitrowithPepMLM-deriveduAbs. (A)Architecture and mechanism of uAb degradation system. CHIP Δ TPR is fused to the C-terminus ofPepMLM-designed target-specific peptides, and can thus tag endogenous target proteins forubiquitin-mediateddegradationintheproteasome, post-plasmidtransfection. (B)Westernblot analysisofHEK293T cells transfected with PepMLM peptides (MSH3_pMLM_1-11). (C) Western blot analysis ofTruHD-Q43Q17McellsexpressingPepMLMpeptides(Q43_pMLM_1-5).Duetoslightvarianceintheloadingcontrollevels,signalintensitiesforQ43_pMLM_3-5werequantifiedusingImageJandplottedusingGraphPad,normalizedtothePolyGcontrol.\n\nFigure4. Screeningof antiviral PepMLM-deriveduAbsinvitro. 20uAbplasmidswereco-transfectedwithplasmid DNA for eachof thephosphoproteinsfrom(A) Nipahvirus, (B) Hendravirus, and(C) Humanmetapneumovirus(HMPV)inHEK293TcellsusingPEI-Max. Wholecell lysateswereharvested48hourspost-transfectionusingRIPAbufferaccordingtothemanufacturer'sprotocol.uAbsandphosphoproteinswereprobedusingmouseanti-FLAGandrabbitanti-HAantibodies,respectively,inadditiontoamouseanti- β- actinloading control antibody. EV is an empty pCAGGS vector and P is a phosphoprotein-only control.Quantificationof reduceddetectionof target PproteinwasdeterminedbydensitometryasdescribedinMaterialsandMethods.\n\nSupplementaryInformation\nPepMLM:TargetSequence-ConditionedGenerationofTherapeuticPeptideBindersviaSpanMaskedLanguageModeling\nTianlaiChen,\n1\nMadeleineDumas,\n2,3\nRioWatson,\n1\nSophiaVincoff,\n1\nChristinaPeng,\n4\nLinZhao,\n1\nLaurenHong,\n1\nSarahPertsemlidis,\n1\nMayumiShaepers-Cheu,\n2\nTianZiWang,\n1\nDivyaSrijay,\n1\nConnorMonticello,\n4\nPranayVure,\n1\nRishabPulugurta,\n1\nKseniiaKholina,\n1\nShreyGoel,\n1\nMatthewP.DeLisa,\n5-7\nRayTruant,\n4\nHectorC.Aguilar,\n2\nPranamChatterjee\n1,8,9,†\n1. DepartmentofBiomedicalEngineering,DukeUniversity2. DepartmentofMicrobiologyandImmunology,CollegeofVeterinaryMedicine,CornellUniversity3. DepartmentofMicrobiology,CollegeofAgricultureandLifeSciences,CornellUniversity4. DepartmentofBiochemistryandBiomedicalSciences,McMasterUniversity5. MeinigSchoolofBiomedicalEngineering,CornellUniversity,Ithaca,NY,USA6. RobertF.SmithSchoolofChemicalandBiomolecularEngineering,CornellUniversity,Ithaca,NY,USA7. CornellInstituteofBiotechnology,CornellUniversity,Ithaca,NY,USA8. DepartmentofComputerScience,DukeUniversity9. DepartmentofBiostatisticsandBioinformatics,DukeUniversity\n†\nCorrespondingauthor:pranam.chatterjee@duke.edu\nSupplementaryFigures\n1. Top-ksamplingandperplexity.2. Associationbetweenmodelperplexityandco-foldingmetrics.3. Visualizationofselectedbinder-proteincomplexes4. EvaluationofPepMLM-3B.\nSupplementaryTables\n1. SettingsandhyperparametersusedtotrainPepMLM-650M.2. Outlieranalysisofprotein-peptidecomplexes.3. Selectedsequenceinformationandfoldingmetricsforthreeclasses.4. PeptidesequencesandPPLscoresforexperimentaltesting.\nSupplementary Figure 1. Top-k sampling and perplexity. ThisfigureillustratesthecorrelationbetweenselectedkvaluesandtheresultingPerplexitywhengeneratingbindersequencesfortargetproteins,whereeachkvaluecorrespondstothegenerationof10binderswithlengthsequatingtothereferencebinder.Askescalates,thereisacorrespondingincreaseinPerplexity,indicatingreducedmodelconfidence.Atk=3,themodelmaintainsalowerPerplexity,signifyinghigherreliabilityinitspredictions.Thechoiceofk=3issupportednotonlybythisenhancedassurancebutalsobyconsiderationsofdiminishingreturns;beyondthispoint,thegain in diversity is outweighed by theincreaseincomplexityandthepotential for atypical predictions.Moreover, practical considerationsfavork=3,asitofferscomputationalefficiencywithoutcompromisingthediversitynecessaryforeffectivebinderdesign.Consequently,k=3isendorsedastheoptimalvaluetoachieveabalancebetweenmodelconfidence,diversityofbindersequences,andcomputationalpragmatism.\n\nSupplementaryFigure2. Associationbetweenmodel perplexityandco-foldingmetrics. (A)RelationshipbetweenipTMandperplexity(PPL). Theinitial segment of FigureApresentsaviolinplot, categorizingperplexityin5-unit intervals. Thesubsequent segment delineatestherawdatapoints, accompaniedbyaregressionanalysis,indicatinganegativecorrelation(Pearsoncorrelationcoefficient-0.414,p<0.001).Theshaded area represents a 95%confidence interval. (B) NegativecorrelationbetweenPPLandpLDDT,identifiedbyPearsoncorrelationcoefficient of -0.490(p<0.001). Theviolinplot underscoresamarkeddecrementinspecificfoldingmetrics,mostpronouncedinipTM,commensuratewithelevatedperplexitylevels.\n\nSupplementary Figure 3. Visualization of binder-proteincomplexes. Co-foldedbinder-proteincomplexesarecategorizedintothreedistinctclassesforvisualizationpurposes.ClassIincludescomplexeswhereboththegeneratedandtestbindersexhibitipTMscores≥0.7,ClassIIencompassesthosewithgeneratedbindershavingipTMscores≥0.7andtestbinderswithipTMscores<0.7,andClassIIIcontainscomplexeswithbothgeneratedandtestbindershavingipTMscores≤0.7.Intheserepresentations,thetargetproteinisdepictedinyellow,whilethePepMLM-generatedbindersandtestbindersareillustratedinredandblue,respectively.Thisclassificationfacilitatesadetailedcomparisonofthestructuralrelationshipsandbindingpatternsamongthedifferentclassesofbinder-proteincomplexes.\n\nSupplementary Figure 4. Evaluationof PepMLM-3B. (A)Perplexitydistributioncomparison.Theperplexityvalueswerecalculatedfortestandgeneratedpeptides,encompassingthetargetproteinsinthetestset.(B)Thedensitydistributionvisualizationofthelogperplexityvaluesfortarget-peptidepairs,encompassingtestpeptides,PepMLM-3B-generatedpeptides,ESM-2-3B-generatedpeptides,andrandompeptides.(C)Insilicohit-rateassessment.UtilizingAlphaFold-Multimer,theipTMscoreswerecomputedforboththegeneratedandtestpeptidesinconjunctionwiththetargetproteinsequence.TheentriesareorganizedinaccordancewiththeipTMscoresattributedtothetest set peptides. Thehit rateischaracterizedbythegeneratedpeptidesexhibitingipTMscores≥thoseofthetestsetpeptides.\n\nSupplementaryTable1. SettingsandhyperparametersusedtotrainPepMLM-650M.\nName Setting\nLearningRate 0.000798\nBatchSize 16\nGradientAccumulation 2\nWarmupsteps 501\nNumberoftrainingepochs 5\nOptimizer AdamW(default)\nTrainer DefaultHuggingFaceSettings\nSupplementary Table 2. Outlier analysis of protein-peptide complexes. This table displays 12protein-peptidecomplexeswithpseudo-perplexity(PPL)valuesexceeding40.IncludedareevaluationmetricsforboththetestcomplexesandthePepMLMgenerationresults,aswellasthebindersequences.ipTMscoresfortestandgeneratedcomplexesarehighlightedindifferentcolorsforcomparison.Notably,eventhoughtheseoutliersexhibithighPPLvaluesindicativeofaccuratemodelingbyPepMLM,themodelremainsproficientingeneratingbindersthatperformequivalentlywellinsilicoasperAlphaFold-MultimeripTMscore.\nTest PepMLMGeneration\nPDBID Binder PPL ipTM pLDDT Binder PPL ipTM pLDDT\n5B5V FLFGSRSS 42.8 0.45 88.9 YHYVMRYA 4.2 0.52 88.7\n4G1C AVXCAX 82.5 0.86 97.0 TAKXST 3.0 0.91 96.9\n2L1C RAKWDTANNPLXKEATSTFTNITXRGT\n45.4 0.49 61.9 HIAEEPHFFESMQNNYEKPTTYKFQQK\n12.0 0.39 73.8\n6GHJ FAQ 209.7 0.71 93.4 MXL 3.4 0.68 93.3\n6AMU MMWDRGLGMM59.2 0.34 87.9 YQALIGGFNA 14.4 0.28 86.1\n5WMR QIKVRVDMV 76.3 0.91 92.3 LRFWRARTL 9.0 0.86 91.8\n5NJC VLEDRI 63.0 0.83 97.5 AAAAAA 1.5 0.74 97.1\n5FML LSNDISQGIKRQRMTVESM\n42.8 0.91 94.0 AAMTKLALAAKTRAQLFKK\n16.1 0.36 87.1\n6DQU GIINTL 65.8 0.87 97.7 YLGANG 5.4 0.84 97.3\n2IWB GHMS 194.0 0.64 96.1 XPPX 4.0 0.67 95.9\n4MLI AHIVMVDAYKPT 62.6 0.87 97.5 GPTPVQVLKRRG17.0 0.53 90.7\n5DHM RSIEISIRVDDFTKTGETVRY\n64.2 0.93 94.4 AQSPEIITADVVVTSDEFTTT\n19.3 0.8 89.6\nSupplementary Table 3. Sequence information and folding metrics for complexes in SupplementaryFigure3.\nPDBID GeneratedBinder plDDT ipTM TestBinder plDDT ipTM\n5GJX RLLEWMIYI 96.3 0.92 RLIQNSITI 96.0 0.92\n2J7X HHLLLHLLTQD 91.9 0.92 IQSLINLLADN 91.9 0.91\n4G1C TAKXST 96.9 0.91 AVXCAX 97.0 0.86\n3TWW RREPPGGAFRX 97.4 0.87 RQSPDGQSFRX 92.7 0.48\n1LCK PPXEEIPP 87.3 0.92 EGQQPQPA 86.1 0.68\n4J79 AARHLD 97.3 0.72 EKVHVQ 97.2 0.64\n5H2F XETNTLVRYVVAHFVLLVSVILIREAPRIESSKXX\n84.9 0.43 XETITYVFIFACIIALFFFAIFFREPPRITXXXXX\n86.7 0.27\n5WS5 SSEEGRPILWIATTTGGGGVIIIVLFLFYAYYGSLSXLXXX\n77.7 0.24 MSEGGRIPLWIVATVAGMGVIVIVGLFFYGAYAGLGSSLXX\n86.4 0.24\n4UY4 ARTKQT 90.1 0.63 ARTXQT 89.0 0.43\nSupplementaryTable4. PeptidesequencesandPPLscoresforexperimental testing. TheaccessionIDsfor NCAM1, MSH3, andHTTarefromUniProt. Viral target sequencesarederivedfromNCBI/GenBankaccessionIDs.\nTarget AccessionID uAbName PeptideSequence DerivationAlgorithm PPL\nNCAM1 P13591 NCAM1_pMLM_1 GKLPLPSLPCK PepMLM 5.343684945\nNCAM1 P13591 NCAM1_pMLM_2 GLGPSPVLPRC PepMLM 5.299030403\nNCAM1 P13591 NCAM1_pMLM_3 GLGPLPVLPCK PepMLM 6.329989946\nNCAM1 P13591 NCAM1_pMLM_4 HSLGQPLSPIC PepMLM 4.753515747\nNCAM1 P13591 NCAM1_RFD_1 SLPIENIYIEA RFDiffusion N/A\nNCAM1 P13591 NCAM1_RFD_2 MKPIEVVYEKA RFDiffusion N/A\nNCAM1 P13591 NCAM1_RFD_3 ELPEQVIYIEA RFDiffusion N/A\nNCAM1 P13591 NCAM1_RFD_4 EKPIEVIYEKA RFDiffusion N/A\nMSH3 P20585 MSH3_pMLM_1SRREQLARILEGAFLASKPepMLM 7.65\nMSH3 P20585 MSH3_pMLM_2SRLEESASAMEASAAQASPepMLM 9.12\nMSH3 P20585 MSH3_pMLM_3SRLKQAKSIMGGSLLLAEPepMLM 9.61\nMSH3 P20585 MSH3_pMLM_4NRLVEALASLEFSAQLSE PepMLM 9.91\nMSH3 P20585 MSH3_pMLM_5SRNKELKSILEFSLAQQK PepMLM 11\nMSH3 P20585 MSH3_pMLM_6SRLKQLASALDGSFLQASPepMLM 11.84\nMSH3 P20585 MSH3_pMLM_7SLRKELASAMEFAAAQSK PepMLM 12.24\nMSH3 P20585 MSH3_pMLM_8SLNEQAASILEAFFAQSS PepMLM 13.47\nMSH3 P20585 MSH3_pMLM_9SYNVELASISEASLAAAK PepMLM 13.69\nMSH3 P20585 MSH3_pMLM_10SLNEQLASIMGGSAQLAEPepMLM 14.11\nMSH3 P20585 MSH3_pMLM_11 SRRVELLSILEFALAAAS PepMLM 14.45\nHTT(Q43) P42858 Q43_pMLM_1 SAAPQLLGSGLALGK PepMLM\nQ43:5.302052023Q17:21.74186374\nHTT(Q43) P42858 Q43_pMLM_2 TAPQLSQASGLAGGK PepMLM\nQ43:6.223211251Q17:22.05928384\nHTT(Q43) P42858 Q43_pMLM_3 LAPQLLLLGLGGLAK PepMLM\nQ43:6.122010055Q17:21.22001317\nHTT(Q43) P42858 Q43_pMLM_4 SAPPQLAAAGGLLLA PepMLM\nQ43:5.42110285Q17:19.667137\nHTT(Q43) P42858 Q43_pMLM_5 SPPPQAAAGAALGAK PepMLM\nQ43:6.196895246Q17:20.36823003\n\nHendravirusP MN062017.1 HeV_1 RLPVYLSLQG PepMLM 3.635173\nHendravirusP MN062017.1 HeV_2 HSPVHLSLLG PepMLM 4.296802\nHendravirusP MN062017.1 HeV_3 SRSVLHSLLQGR PepMLM 4.974103\nHendravirusP MN062017.1 HeV_4 HSSVLQSLFGG PepMLM 5.449664\nHendravirusP MN062017.1 HeV_5 SESLYLSLFKG PepMLM 6.702855\nHendravirusP MN062017.1 HeV_6 SMSRRRQLAKKLLLLAIKSPepMLM 6.707319\nHendravirusP MN062017.1 HeV_7 RQSLRQQLLLDLGR PepMLM 6.74773\nHendravirusP MN062017.1 HeV_8 SSLVYLSLGA PepMLM 6.824329\nHendravirusP MN062017.1 HeV_9 HLSLPHSLLQKR PepMLM 6.850688\nHendravirusP MN062017.1 HeV_10 SMSVEKSLSKKLGKKLIKSPepMLM 6.855796\nHendravirusP MN062017.1 HeV_11 RSLVKKQLLLKLLG PepMLM 6.950253\nHendravirusP MN062017.1 HeV_12 MQSVKLKLLLKGLLR PepMLM 7.039044\nHendravirusP MN062017.1 HeV_13 HSSVLQQLFGE PepMLM 7.046471\nHendravirusP MN062017.1 HeV_14 HHSLLQSLLQGT PepMLM 7.287729\nHendravirusP MN062017.1 HeV_15 RLPLYLSLGA PepMLM 7.372559\nHendravirusP MN062017.1 HeV_16 HHSLLHSLLKGT PepMLM 7.621191\nHendravirusP MN062017.1 HeV_17 RLSVLQQLLKLGG PepMLM 7.758791\nHendravirusP MN062017.1 HeV_18 SLSRRQQLLLDLGK PepMLM 7.797618\nHendravirusP MN062017.1 HeV_19 SKPLYLLLGG PepMLM 7.82979\nHendravirusP MN062017.1 HeV_20 RLSVRKLLLLDLGK PepMLM 7.860104\nHMPVP AAS22075.1 HMPV_1 LTLEQLQEKR PepMLM 6.510858\nHMPVP AAS22075.1 HMPV_2 TLEEELLLKR PepMLM 7.514123\nHMPVP AAS22075.1 HMPV_3 LTLEQLQLIR PepMLM 7.855078\nHMPVP AAS22075.1 HMPV_4 AELLLRQQQLLL PepMLM 7.869746\nHMPVP AAS22075.1 HMPV_5 SVLTAEQLIKI PepMLM 8.039237\nHMPVP AAS22075.1 HMPV_6 DLRRRLAEKTPELQLLLI PepMLM 8.068756\nHMPVP AAS22075.1 HMPV_7 ALLAKKLTLEALLAL PepMLM 8.235918\nHMPVP AAS22075.1 HMPV_8 AEEAKKLTEELLRLR PepMLM 8.411599\nHMPVP AAS22075.1 HMPV_9 DTELAAKKLTTELLLKI PepMLM 8.626335\nHMPVP AAS22075.1 HMPV_10 TLTLQQLLKL PepMLM 8.713968\n",
  "topic": "In silico",
  "concepts": [
    {
      "name": "In silico",
      "score": 0.6574392318725586
    },
    {
      "name": "Computational biology",
      "score": 0.6308490037918091
    },
    {
      "name": "Peptide",
      "score": 0.5233991742134094
    },
    {
      "name": "Sequence (biology)",
      "score": 0.508124828338623
    },
    {
      "name": "Computer science",
      "score": 0.5056288242340088
    },
    {
      "name": "Biology",
      "score": 0.3001628816127777
    },
    {
      "name": "Biochemistry",
      "score": 0.23900192975997925
    },
    {
      "name": "Gene",
      "score": 0.0
    }
  ],
  "institutions": [
    {
      "id": "https://openalex.org/I170897317",
      "name": "Duke University",
      "country": "US"
    }
  ]
}